Amneal Pharmaceuticals, Inc. 8-K

What Happened
Amneal Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued May 7, 2026. The company filed a Form 8-K (Item 2.02) to furnish that press release (Exhibit 99.1) and incorporated the release by reference into the report. The filing was signed by Anastasios Konidaris, Executive Vice President and Chief Financial Officer.

Key Details

• Filing date: May 7, 2026; reporting period: quarter ended March 31, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition) — press release attached as Exhibit 99.1.
• Administrative exhibit disclosure: cover page in Inline XBRL included (Exhibit 104).
• Form 8-K signed by CFO Anastasios Konidaris (Principal Financial and Accounting Officer).

Why It Matters
This 8-K signals that Amneal has released its quarterly earnings and related financial information; investors should review the attached press release for revenue, earnings, guidance and other operating metrics that can affect valuation and near-term stock performance. The filing itself confirms the company has formally furnished those results to the market and complied with SEC disclosure requirements.